Guo Huang - Publications

Retraction Note: ALKBH5 inhibits thyroid cancer progression by promoting ferroptosis through TIAM1-Nrf2/HO-1 axis.

Journal: Molecular and cellular biochemistry

Published: March 11, 2026

Removal of nonspecific binding proteins is required in co-immunoprecipitation with nuclear proteins.

Journal: BioTechniques

Published: November 19, 2022

Deciphering a mitochondria-related signature to supervise prognosis and immunotherapy in hepatocellular carcinoma.

Journal: Frontiers in immunology

Published: October 15, 2022

Phospholipase C delta 1 inhibits WNT/β-catenin and EGFR-FAK-ERK signaling and is disrupted by promoter CpG methylation in renal cell carcinoma.

Journal: Clinical epigenetics

Published: September 05, 2022

Roles of oncogenes in esophageal squamous cell carcinoma and their therapeutic potentials.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: July 19, 2022

Identification of a New Prediction Model for Bladder Cancer Related to Immune Functions and Chemotherapy Using Gene Sets of Biological Processes.

Journal: BioMed research international

Published: May 15, 2022

ALKBH5 inhibits thyroid cancer progression by promoting ferroptosis through TIAM1-Nrf2/HO-1 axis.

Journal: Molecular and cellular biochemistry

Published: March 16, 2022

A novel epithelial-mesenchymal transition gene signature for the immune status and prognosis of hepatocellular carcinoma.

Journal: Hepatology international

Published: December 15, 2021

Epigenetic modification and BRAF gene mutation in thyroid carcinoma.

Journal: Cancer cell international

Published: October 20, 2021

Overexpression of Epidermal Growth Factor Receptor (EGFR) and HER-2 in Bladder Carcinoma and Its Association with Patients' Clinical Features.

Journal: Medical science monitor : international medical journal of experimental and clinical research

Published: October 09, 2018